跳至主要内容
临床试验/NL-OMON53741
NL-OMON53741招募中不适用

A comparison between Qutenza and duloxetine for the treatment of painful chemotherapy-induced peripheral neuropathy (QULOX): a pragmatic randomized controlled trial - QULOX study

Amsterdam UMC0 个研究点目标入组 103 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
103

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age >= 18 years of age
  • - Presence of CIPN grade 1 or higher according to the NCIC-CTC
  • - Treatment with chemotherapy in the last 5 years
  • - Able to give oral and written informed consent
  • - Painful neuropathy with mean pain (1 week) score of >= 4

排除标准

  • - Peripheral neuropathy from other causes (e.g. carpal/tarsal tunnel syndrome,
  • radiculopathy,
  • spinal stenosis, brachial plexopathy)
  • - Leptomeningeal carcinomatosis
  • - Use of selective serotonin reuptake inhibitors, exchanging for medication
  • without interaction is
  • possible following expertise of the pain specialist anti-depressant
  • - Psychiatric disorders which can interfere with cooperation
  • - Abnormal renal (< GFR 30) or liver function tests (> 2 times normal value)
  • - Severe heart failure as determined by the cardiologist
  • - Allergy for duloxetine or capsaicin
  • - Skin diseases in hands and/or feet, damaged skin
  • - The presence of uncontrolled/untreated hypertension
  • - Concomitant use of medication that may interact with duloxetine such as
  • fluvoxamine, ciprofloxacin and enoxacin which is not replaceable and according
  • to the treating specialist not safe to combine with duloxetine
  • - Any condition that by the judgement of the investigator might interfere with
  • the investigation
  • - Previous treatment with Qutenza or duloxetine for CIPN

研究者

发起方
Amsterdam UMC

相似试验